Clinical Trials | December 03, 2025
AbbVie’s Atogepant shows breakthrough results for acute migraine relief
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
Suffering from acute migraine? You may soon bid adieu to the debilitating headache
This is the first time in history that an NDA for a New Chemical Entity (NCE) from an Indian pharmaceutical company has been filed and accepted by the USFDA
Fresh Phase 1b/2a data highlight the strength of the iberdomide + daratumumab + dexamethasone combination in transplant-deferred or ineligible NDMM
Patients can now get the starting 2.5 mg dose for $299 per month
At the heart of the showdown is a deep split among federal circuit courts over whether federal law overrides state failure-to-warn claims in Roundup personal-injury suits
Selected proposals in the innovation challenge will receive funding to develop transformative ideas, tools, and approaches to strengthen early diagnosis and improve patient outcomes
Ascelis Center of Excellence for Peptide Development and Characterization will drive the development of cosmetic, therapeutic, and pharmaceutical peptides
Ilumya is the first IL-23 inhibitor to complete five years of study based on a pooled analysis of two Phase 3 efficacy and safety extension trials
Roche says the move marks a step forward in its digital transformation strategy
LANXESS Biosecurity Solutions aims to deliver “advanced disinfection and hygiene solutions to support Indian farmers in maintaining healthier and safer farm environments
Subscribe To Our Newsletter & Stay Updated
